Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD7503 · 1 trial · 4 indications
To assess adverse events as a variable of safety and tolerability of AZD7503 following SC single dose administration.
| Arm | Type | Description |
|---|---|---|
| Cohort 1: AZD7503 dose 1 | EXPERIMENTAL | Randomised healthy participants will receive a single dose 1 of AZD7503. |
| Cohort 2: AZD7503 dose 2 | EXPERIMENTAL | Randomised healthy participants will receive a single dose 2 of AZD7503. |
| Cohort 3: AZD7503 dose 3 | EXPERIMENTAL | Randomised healthy participants will receive a single dose 3 of AZD7503. |
| Cohort 4: AZD7503 dose 4 | EXPERIMENTAL | Randomised healthy participants will receive a single dose 4 of AZD7503. |
| Cohort 5 : AZD7503 dose X | EXPERIMENTAL | Randomised healthy participants will receive a single dose X of AZD7503. |
| Cohort 6: AZD7503 dose Y | EXPERIMENTAL | Randomised healthy participants will receive a single dose Y of AZD7503. |
| Pooled Placebo for AZD7503 (Cohorts 1 to 6) | PLACEBO_COMPARATOR | Randomised healthy participants will receive placebo. |
| Japanese Cohort 1: AZD7503 dose 3 | EXPERIMENTAL | Randomised healthy Japanese participants will receive a single dose 3 of AZD7503. |
| Japanese Cohort 2: AZD7503 dose 4 | EXPERIMENTAL | Randomised healthy Japanese participants will receive a single dose 4 of AZD7503. |
| Placebo (Japanese Cohorts) | PLACEBO_COMPARATOR | Randomised healthy Japanese participants will receive placebo. |
| Chinese Cohort: AZD7503 dose 4 | EXPERIMENTAL | Randomised healthy Chinese participants will receive a single dose 4 of AZD7503. |
| Placebo (Chinese Cohort) | PLACEBO_COMPARATOR | Randomised healthy Chinese participants will receive placebo. |
| Name | Type | Description |
|---|---|---|
| AZD7503 | DRUG | Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y). |
| Placebo | DRUG | Randomised participants will receive placebo by SC injection |
Inclusion Criteria: * Healthy non smoking male and/or female (of non childbearing potential) participants with suitable veins for cannulation or repeated venipuncture. * Females must have a negative pregnancy test at screening and on admission to the study centre, must not be lactating and must be ...
AZD7503 is an investigational small molecule being studied for safety, tolerability, and pharmacokinetics in healthy participants. It is currently in Phase 1 clinical development and is not approved for any medical use.
AZD7503 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN.
AZD7503 is in Phase 1 clinical development. A Phase 1 study assessing its safety, tolerability, and pharmacokinetics in healthy participants has been completed.
AZD7503 has one completed Phase 1 clinical trial, identified as NCT05143905. This study assessed the safety, tolerability, and pharmacokinetics of AZD7503 in healthy participants in the United States.
AZD7503 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial, but it remains in clinical development and has not been approved for any use.